Results 41 to 50 of about 38,544 (277)

HIV Integrase Inhibitors

, 2013
This chapter presents the discovery, development and evolution of integrase strand transfer inhibitors. A brief overview of the first‐generation inhibitors raltegravir and elvitegravir serves to describe their landmark advancement of the field and also outline areas for further improvement.
Mathieu Métifiot, Christophe Marchand, Yves Pommier   +2 more
openaire   +3 more sources

Lipid abnormality correction by integrase inhibitor among children taking ARt

Журнал инфектологии, 2019
Goal. To estimate a possibility of correction laboratory abnormalities (increased level of cholesterol and/or triglycerides at blood of HIV-positive children) by switch the boosted PI on HIV integrase inhibitor (Raltegravir). Methods.
A. V. Samarina, N. S. Dyldina, E. K. Fertikh, E. B. Yastrebova, I. A. Abramova, D. A. Gusev   +5 more
doaj   +1 more source

Pyrone-based inhibitors of metalloproteinase types 2 and 3 may work as conformation-selective inhibitors. [PDF]

, 2011
Matrix metalloproteinases are zinc-containing enzymes capable of degrading all components of the extracellular matrix. Owing to their role in human disease, matrix metalloproteinase have been the subject of extensive study.
de Oliveira, César AF, Durrant, Jacob D, McCammon, J Andrew   +2 more
core   +1 more source

A Fluorescent Assay to Search for Inhibitors of HIV-1 Integrase Interactions with Human Ku70 Protein, and Its Application for Characterization of Oligonucleotide Inhibitors

Biomolecules, 2020
The search for compounds that can inhibit the interaction of certain viral proteins with their cellular partners is a promising trend in the development of antiviral drugs.
Simon Galkin, Anna Rozina, Arthur Zalevsky, Marina Gottikh, Andrey Anisenko   +4 more
doaj   +1 more source

Protein expression from unintegrated HIV-1 DNA introduces bias in primary in vitro post-integration latency models [PDF]

, 2016
To understand the persistence of latently HIV-1 infected cells in virally suppressed infected patients, a number of in vitro models of HIV latency have been developed.
Bonczkowski, Pawel, Borch, Alexandra, De Scheerder, Marie-Angélique, De Spiegelaere, Ward, Koenig, Renate, Malatinková, Eva, Melkova, Zora, Vandekerckhove, Linos   +7 more
core   +1 more source

A Comprehensive Literature Review of Treatment-Emergent Integrase Resistance with Dolutegravir-Based Regimens in Real-World Settings

Viruses, 2023
After a decade of dolutegravir (DTG) use in various antiretroviral therapy combinations and in diverse populations globally, it is critical to identify HIV strains with reduced drug susceptibility and monitor emergent resistance in people living with HIV
Cassidy Henegar, Emilio Letang, Ruolan Wang, Charles Hicks, Dainielle Fox, Bryn Jones, Annemiek de Ruiter, Vani Vannappagari   +7 more
doaj   +1 more source

Dynein Regulators Are Important for Ecotropic Murine Leukemia Virus Infection [PDF]

, 2016
Indexación: Web of Science.During the early steps of infection, retroviruses must direct the movement of the viral genome into the nucleus to complete their replication cycle.
Arriagada, Gloria, Cancino, Jorge, Goff, Stephen P., Opazo, Tatiana, Valle-Tenney, Roger   +4 more
core   +1 more source

Dolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kinetics.

PLoS ONE, 2013
Signature HIV-1 integrase mutations associated with clinical raltegravir resistance involve 1 of 3 primary genetic pathways, Y143C/R, Q148H/K/R and N155H, the latter 2 of which confer cross-resistance to elvitegravir. In accord with clinical findings, in
Felix DeAnda, Kendra E Hightower, Robert T Nolte, Kazunari Hattori, Tomokazu Yoshinaga, Takashi Kawasuji, Mark R Underwood   +6 more
doaj   +1 more source

Viral Dynamic Model of Antiretroviral Therapy Including the Integrase Inhibitor Raltegravir in Patients with HIV-1

Biomath, 2012
Antiviral combination therapies consisting of reverse transcriptase inhibitors, protease inhibitors and an integrase inhibitor, have been developed to suppress HIV below the limit of detection.
Dimitra Bon, Christoph Stephan, Oliver Keppler, Eva Herrmann   +3 more
doaj   +1 more source

Structural Basis for Inhibitor-Induced Aggregation of HIV Integrase. [PDF]

PLoS Biology, 2016
The allosteric inhibitors of integrase (termed ALLINIs) interfere with HIV replication by binding to the viral-encoded integrase (IN) protein. Surprisingly, ALLINIs interfere not with DNA integration but with viral particle assembly late during HIV ...
Kushol Gupta, Vesa Turkki, Scott Sherrill-Mix, Young Hwang, Grant Eilers, Louis Taylor, Charlene McDanal, Ping Wang, David Temelkoff, Robert T Nolte, Emile Velthuisen, Jerry Jeffrey, Gregory D Van Duyne, Frederic D Bushman   +13 more
doaj   +1 more source